Impact Factor 5.555 | CiteScore 5.1
More on impact ›

CORRECTION article

Front. Endocrinol., 28 June 2021 | https://doi.org/10.3389/fendo.2021.705241

Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues

  • 1Barrow Pituitary Center, Barrow Neurological Institute, Departments of Neuroendocrinology and Neurosurgery, University of Arizona College of Medicine and Creighton School of Medicine, Phoenix, AZ, United States
  • 2Division of Pediatric Endocrinology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States
  • 3SEMPR, Serviço de Endocrinologia e Metabologia, Departamento de Clínica Médica, Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Brazil
  • 4Department of Medicine, VA Palo Alto Health Care System and Stanford University School of Medicine, Palo Alto, CA, United States

A Corrigendum on
Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs

by Yuen KCJ, Miller BS, Boguszewski CL, Hoffman AR. (2021). Front. Endocrinol. 12:637209. doi: 10.3389/fendo.2021.637209

Error in Table 1, 5th column, 19th row

In the original article, there was a mistake in Table 1 as published. In Table 1, 5th column, 19th row, the company “Alteogen” under the “Current Status” column was incorrectly stated that the company was “bankrupt in 2009”. This statement is incorrect as the company remains a currently viable bio-tech company globally.

TABLE 1
www.frontiersin.org

Table 1 Overview of the development history of LAGH analogues.

The authors apologize for this inadvertent error with the statement and a modified Table 1 is provided below, where the statement “bankrupt in 2009” is now deleted. This new table does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: long-acting growth hormone, treatment adherence, growth hormone deficiency, growth hormone replacement, adults, children

Citation: Yuen KCJ, Miller BS, Boguszewski CL and Hoffman AR (2021) Corrigendum: Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogues. Front. Endocrinol. 12:705241. doi: 10.3389/fendo.2021.705241

Received: 04 May 2021; Accepted: 24 May 2021;
Published: 28 June 2021.

Edited by:

Ilonka Kreitschmann-Andermahr, University of Duisburg-Essen, Germany

Reviewed by:

Martin Bidlingmaier, Ludwig Maximilian University of Munich, Germany
Roberto Salvatori, Johns Hopkins University, United States

Copyright © 2021 Yuen, Miller, Boguszewski and Hoffman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Kevin C. J. Yuen, kevin.yuen@dignityhealth.org